Effect of prostaglandin I2 analogue TRK-100 on the suppression of intimal fibrous proliferation.
This study investigated the effect of prostaglandin I2 analogue (TRK-100) on the healing of arterial anastomoses. The infrarenal abdominal aorta was divided and reanastomosed immediately in rabbits. A control group of rabbits were fed commercial rabbit food (ORC 4); a cholesterol group of rabbits were fed a diet with 1% cholesterol added to ORC 4; and a TRK group of rabbits received the same diet as the cholesterol group, but TRK-100 was given subcutaneously at a dose of 0.3 mg (TRK-I group) or 1.0 mg (TRK-II group) every other day. After 3 months a blood sample was taken for biochemical analysis, and the abdominal aorta was harvested for histologic examination. The serum lipid and thromboxane B2 concentrations and the thromboxane B2/6-keto prostaglandin F1 alpha ratio in the TRK groups were significantly lower than in the cholesterol group. The proliferative connective tissue did not cover the anastomotic suture line in either the control or the TRK groups. However, the suture line was covered completely by connective tissue in the cholesterol group. Intimal thickness in the cholesterol group was greater than in either the control or the TRK-II group (p less than 0.01 and p less than 0.05, respectively). These data suggest that TRK-100 may suppress intimal fibrous proliferation at anastomotic suture lines by a mechanism affecting the thromboxane B2/6-keto prostaglandin F1 alpha ratio.
Kouchi
Y
Y
First Department of Surgery, Yamaguchi University School of Medicine, Japan.
Esato
K
K
O-Hara
M
M
Zempo
N
N
D000704:Analysis of Variance; D000714:Anastomosis, Surgical; D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D001792:Blood Platelets / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005355:Fibrosis / Q000517:prevention & control; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011817:Rabbits
D002791:Cholesterol, Dietary; D010975:Platelet Aggregation Inhibitors; C048081:beraprost; D002784:Cholesterol; D011464:Epoprostenol